Ribociclib (Kisqali) falls under the inhibitor of cyclin D1/CDK4 and CDK6, and originated in order to treat certain sorts of breast cancer.
This inhibitor is also being investigated in the form of treatment for certain other drug resistant cancers. Ribociclib was developed by Astex Pharma and Novartis.
In the month of March, 2017, the Food and Drug Administration approved ribociclib for the treatment of HR+/HER2- Metastatic Breast Cancer.
In the month of July, 2018, ribociclib was approved for the additional indications in the HR+/HER2- Advanced Breast Cancer.
The ribociclib 200 mg price in India is around 20,250 INR for a supply of 21 tablets, depending on the pharmacy/wholesaler you visit. Any WHO-GDP & ISO certified pharmaceutical wholesaler company would be best to buy ribociclib.
